Sellas Life Sciences Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
SELLAS Life Sciences Group files its 2024 10-K, highlighting clinical trial progress for GPS and SLS009 while reporting a net loss of $30.9 million.
NASDAQ
SELLAS Life Sciences Group announces executive departures, provides updates on clinical trials for GPS and SLS009, and discloses financial details.